By last fall, there were increasing signs that Hims & Hers’s ability to sell its imitation semaglutide was nearing an end. The FDA in October said the shortage of Eli Lilly’s weight-loss drug ...

Weight loss drugs are getting more popular, even for teenagers and pre-teens -- but while many doctors have reported ...

Hims & Hers Health announced today that it has entered into “a long-term collaboration” with Danish drugmaker Novo Nordisk to offer its popular weight-loss drug Wegovy to its users through the ...

This new offering builds on Hims & Hers’ existing suite of weight loss solutions and provides self-pay patients with access to all dose strengths of Wegovy in a high-quality pen. The platform ...

That partnership will see Hims & Hers offer Novo Nordisk’s weight-loss drug Wegovy through its platform ... that it would stop offering compounded semaglutide, the active ingredient used ...

That partnership will see Hims & Hers offer Novo Nordisk’s weight-loss drug Wegovy ... a compounded semaglutide due to a semaglutide shortage. But once the U.S. Food and Drug Administration ...

Novo Nordisk on Tuesday said it will offer its weight loss drug ... Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's diabetes drug Ozempic and ...

The FDA allowed this because there was a shortage of semaglutide ... Hers Health aren’t groundbreaking. However, the company is doing what it can to maintain interest in its weight loss drug ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is still a buy.

Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's diabetes drug Ozempic and Wegovy, in May of 2024. The company has largely had to stop offering the ...

a 70-year-old woman on compounded tirzepatide, the drug has transformed her ... for weight loss and describing their experiences using them. These include the usual suspects, like semaglutide ...